The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Discovery of Vinyl Sulfones as a Novel Class of Neuroprotective Agents toward Parkinson’s Disease Therapy
Abstract
Although the etiology of Parkinson's disease (PD) remains elusive, recent studies suggest that oxidative stress contributes to the cascade leading to dopaminergic (DAergic) neurodegeneration. The Nrf2 signaling is the main pathway responsible for cellular defense system against oxidative stress. Nrf2 is a transcription factor that regulates environmental stress response by inducing expression of antioxidant enzyme genes. We have synthesized novel vinyl sulfone derivatives. They exhibited a broad range of activities in inducing HO-1, whose gene expression is under the control of Nrf2. Among them, compound 12g was confirmed to activate Nrf2 and induce expression of the Nrf2-dependent antioxidant enzymes NQO1, GCLC, GLCM, and HO-1, at both mRNA and protein levels in DAergic neuronal cells. This was accompanied by protection of DAergic neurons in both in vitro and MPTP-induced in vivo models of PD. In addition, compound 12g effectively resulted in attenuation of the PD-associated behavioral deficits in the mouse model.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
Uttara, B., Singh, A., Zamboni, P., & Mahajan, R. (2009) · Current Neuropharmacology · doi:10.2174/157015909787602823 · Cited by 3,378
NRF2 and cancer: the good, the bad and the importance of context
Sporn, M. B., & Liby, K. T. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3278 · Cited by 1,067
Wakabayashi, N., Dinkova-Kostova, A. T., Holtzclaw, W. D., Kang, M.-I., Kobayashi, A., Yamamoto, M., Kensler, T. W., & Talalay, P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307301101 · Cited by 986
Gilgun-Sherki, Y., Melamed, E., & Offen, D. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00019-3 · Cited by 838
Role of Oxidative Stress in Parkinson's Disease
Hwang, O. (2013) · Experimental Neurobiology · doi:10.5607/en.2013.22.1.11 · Cited by 835
Self-citationStress-activated cap’n’collar transcription factors in aging and human disease
Sykiotis, G. P., & Bohmann, D. (2010) · Science Signaling · doi:10.1126/scisignal.3112re3 · Cited by 776
Expression of Nrf2 in Neurodegenerative Diseases
Ramsey, C. P., Glass, C. A., Montgomery, M. B., Lindl, K. A., Ritson, G. P., Chia, L. A., Hamilton, R. L., Chu, C. T., & Jordan-Sciutto, K. L. (2007) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/nen.0b013e31802d6da9 · Cited by 760
The Nrf2–ARE Pathway: An Indicator and Modulator of Oxidative Stress in Neurodegeneration
Johnson, J. A., Johnson, D. A., Kraft, A. D., Calkins, M. J., Jakel, R. J., Vargas, M. R., & Chen, P. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.036 · Cited by 589
Chen, P.-C., Vargas, M. R., Pani, A. K., Smeyne, R. J., Johnson, D. A., Kan, Y. W., & Johnson, J. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813361106 · Cited by 579
Priorities in Parkinson's disease research
Meissner, W. G., Frasier, M., Gasser, T., Goetz, C. G., Lozano, A., Piccini, P., Obeso, J. A., Rascol, O., Schapira, A., Voon, V., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3430 · Cited by 436
de Vries, H. E., Witte, M., Hondius, D., Rozemuller, A. J. M., Drukarch, B., Hoozemans, J., & van Horssen, J. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.09.001 · Cited by 428
Oxidative Stress and Genetics in the Pathogenesis of Parkinson's Disease
Zhang, Y., Dawson, V. L., & Dawson, T. M. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0319 · Cited by 407
Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease
Rojo, A. I., Innamorato, N. G., Martín‐Moreno, A. M., De Ceballos, M. L., Yamamoto, M., & Cuadrado, A. (2010) · Glia · doi:10.1002/glia.20947 · Cited by 375
Testa, C. M., Sherer, T. B., & Greenamyre, J. T. (2005) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.11.007 · Cited by 299
Giudice, A., Arra, C., & Turco, M. C. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-738-9_3 · Cited by 256
Kweon, M.-H., Adhami, V. M., Lee, J.-S., & Mukhtar, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604748200 · Cited by 250
Self-citationEvaluation and Discovery of Novel Synthetic Chalcone Derivatives as Anti-Inflammatory Agents
Wu, J., Li, J., Cai, Y., Pan, Y., Ye, F., Zhang, Y., Zhao, Y., Yang, S., Li, X., & Liang, G. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200946h · Cited by 222
Targeting Heme Oxygenase-1 for Neuroprotection and Neuroinflammation in Neurodegenerative Diseases
Jazwa, A., & Cuadrado, A. (2010) · Current Drug Targets · doi:10.2174/1389450111009011517 · Cited by 209
Suri, C., Fung, B., Tischler, A., & Chikaraishi, D. (1993) · The Journal of Neuroscience · doi:10.1523/jneurosci.13-03-01280.1993 · Cited by 183
Yang, L., Calingasan, N. Y., Thomas, B., Chaturvedi, R. K., Kiaei, M., Wille, E. J., Liby, K. T., Williams, C., Royce, D., Risingsong, R., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005757 · Cited by 172
Kaidery, N. A., Banerjee, R., Yang, L., Smirnova, N. A., Hushpulian, D. M., Liby, K. T., Williams, C. R., Yamamoto, M., Kensler, T. W., Ratan, R. R., et al. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4491 · Cited by 170
Novel Chalcone Derivatives as Potent Nrf2 Activators in Mice and Human Lung Epithelial Cells
Kumar, V., Kumar, S., Hassan, M., Wu, H., Thimmulappa, R. K., Kumar, A., Sharma, S. K., Parmar, V. S., Biswal, S., & Malhotra, S. V. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2002348 · Cited by 165
Protective Effect of Sulforaphane against Dopaminergic Cell Death
Han, J. M., Lee, Y. J., Lee, S. Y., Kim, E., Moon, Y., Kim, H. W., & Hwang, O. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.110866 · Cited by 146
Self-citationKim, S. T., Son, H. J., Choi, J. H., Ji, I. J., & Hwang, O. (2009) · Brain Research · doi:10.1016/j.brainres.2009.09.103 · Cited by 89
Self-citationThe transcription factor Nrf2 as a new therapeutic target in Parkinson's disease
Cuadrado, A., Moreno-Murciano, P., & Pedraza-Chaverri, J. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/13543780802716501 · Cited by 83
Choi, H. J., Jang, Y. J., Kim, H. J., & Hwang, O. (2000) · Molecular Pharmacology · doi:10.1124/mol.58.3.633 · Cited by 71
Self-citationLocalization of GTP cyclohydrolase in monoaminergic but not nitric oxide-producing cells
Hwang, O., Baker, H. A., Gross, S. S., & JOH, T. H. (1998) · Synapse · Cited by 62
Self-citationA Synthetic Chalcone as a Potent Inducer of Glutathione Biosynthesis
Kachadourian, R., Day, B. J., Pugazhenti, S., Franklin, C. C., Genoux‐Bastide, E., Mahaffey, G., Gauthier, C., Pietro, A. D., & Boumendjel, A. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm2016073 · Cited by 58
Choi, H. J., Lee, S. Y., Cho, Y., No, H., Kim, S. W., & Hwang, O. (2005) · Neurochemistry International · doi:10.1016/j.neuint.2005.10.011 · Cited by 58
Self-citationPreventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation
Asanuma, M., Miyazaki, I., Diaz-Corrales, F. J. J., Miyoshi, K., Ogawa, N., & Murata, M. (2007) · Neuroscience Research · doi:10.1016/j.neures.2007.10.002 · Cited by 45
Son, H. J., Lee, J. A., Shin, N., Choi, J. H., Seo, J. W., Yoon, D., Lee, C.-S., Kim, E., Choe, H., & Hwang, O. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01692.x · Cited by 26
Self-citationJNK activation by tetrahydrobiopterin: Implication for Parkinson's disease
Choi, H. J., Lee, S. Y., Cho, Y., & Hwang, O. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20012 · Cited by 26
Self-citationLim, J. H., Kim, S. S., Boo, D. H., No, H., Kang, B. Y., Kim, E., Hwang, O., & Choi, H. J. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2008.12.056 · Cited by 26
Self-citationChoi, H. J., Kim, S. W., Lee, S. Y., Moon, Y. W., & Hwang, O. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00054-2 · Cited by 24
Self-citationInactivation of Aconitase by Tetrahydrobiopterin in DArgic Cells: Relevance to PD
Yoon, N. S., Cho, Y., Lee, S. Y., Choi, H. J., & Hwang, O. (2010) · Experimental Neurobiology · doi:10.5607/en.2010.19.1.23 · Cited by 12
Self-citation
Cited by
The emerging role of Nrf2 in mitochondrial function
Dinkova-Kostova, A. T., & Abramov, A. Y. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.04.036 · Cited by 983
Tebay, L. E., Robertson, H., Durant, S. T., Vitale, S. R., Penning, T. M., Dinkova-Kostova, A. T., & Hayes, J. D. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.021 · Cited by 837
Buendia, I., Michalska, P., Navarro, E., Gameiro, I., Egea, J., & León, R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.11.003 · Cited by 678
Sivandzade, F., Prasad, S., Bhalerao, A., & Cucullo, L. (2019) · Redox Biology · doi:10.1016/j.redox.2018.11.017 · Cited by 639
Nrf2—a therapeutic target for the treatment of neurodegenerative diseases
Johnson, D. A., & Johnson, J. A. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.07.147 · Cited by 321
Metadata
- Authors
- Woo, S. Y., Kim, J. H., Moon, M. K., Han, S.-H., Yeon, S. K., Choi, J. W., Jang, B. K., Song, H. J., Kang, Y. G., Kim, J. W., Lee, J., Kim, D. J., Hwang, O., & Park, K. D.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2014-02-05
- Volume
- 57
- Issue
- 4
- Pages
- 1473-1487
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2030117581
- Cited by
- 263
- References
- 36
- FWCI
- 10.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.